留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

解毒破瘀法抑制三阴性乳腺癌复发与转移的临床研究

刘敏 王明武

刘敏, 王明武. 解毒破瘀法抑制三阴性乳腺癌复发与转移的临床研究[J]. 南京中医药大学学报, 2016, 32(2): 111-113.
引用本文: 刘敏, 王明武. 解毒破瘀法抑制三阴性乳腺癌复发与转移的临床研究[J]. 南京中医药大学学报, 2016, 32(2): 111-113.
LIU Min, WANG Ming-wu. Clinical Research on the Inhibition of Recurrence and Metastasis of Triple Negative Breast Cancer with the Method of Detoxification and Blood Stasis Dissipating[J]. Journal of Nanjing University of traditional Chinese Medicine, 2016, 32(2): 111-113.
Citation: LIU Min, WANG Ming-wu. Clinical Research on the Inhibition of Recurrence and Metastasis of Triple Negative Breast Cancer with the Method of Detoxification and Blood Stasis Dissipating[J]. Journal of Nanjing University of traditional Chinese Medicine, 2016, 32(2): 111-113.

解毒破瘀法抑制三阴性乳腺癌复发与转移的临床研究

Clinical Research on the Inhibition of Recurrence and Metastasis of Triple Negative Breast Cancer with the Method of Detoxification and Blood Stasis Dissipating

  • 摘要: 目的 观察解毒破瘀法抑制三阴性乳腺癌(TNBC)复发与转移的临床疗效。方法 40例三阴性乳腺癌术后患者随机分为治疗组和对照组,各20例,对照组根据辨证施治随证加减,治疗者在辨证施治的同时加用解毒破瘀法,治疗3年,观察3年无病生存率(DFS)。结果 治疗组20例患者3年DFS为100%,对照组为75%,P<0.05。结论 解毒破瘀法能有效抑制三阴性乳腺癌复发及转移。

     

  • [1] WHO. Globocan 2008:Estimated cancer as global health concern[J].Cancer incidence, mortality prevalence and disability-adjusted life years(DALYs) worldwise in 2008,2nd January 2013[OL]. http://globocan.iarc.fr/(22 February 2013, date last accessed).
    [2] Ossovskaya V, Wang Y, Budoff A, et al. Exploring molecular pathways of triple-negative breast cancer[J]. Genes Cancer, 2011, 2(9): 870-879.
    [3] 欧江华,蒋威华,倪多,等.新疆地区三阴性乳腺癌病理特征及预后分析[J].中国肿瘤临床,2011,38(18):1159-1162.
    [4] Ou JH, Jiang WH, Ni D, et al. Analysis on pathological feature and prognosis of triple negative breast cancer in Xinjiang aera[J]. Chin J Clin Oncol, 2011, 38(18): 1159-1162.
    [5] Baner KR, Brown M, Cress RD, et al. Descoiptive analysis of estrogen receptor(ER)-negative,progesterone receptor(PR)-negative,and HER2-negative phenotype a population-based study from the California cancer registry[J]. Cancer, 2007, 109(9): 1721-1728.
    [6] Tischkowitz M, Brunet JS, Bégin LR, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer[J]. BMC Cancer, 2007, 7: 134.
    [7] AJCC癌症分期手册[M].严正,译.广州:中山大学肿瘤防治中心,2010.
    [8] AJCC. The Cancer Staging Manual[M]. Translated by Yan Z. Guangzhou: Sun Yat-Sen University Cancer Center, 2010.
    [9] 江泽飞,胡夕春, 王永胜,等.现代乳腺癌全程管理新理念和临床策略[M].上海:上海科技出版社,2013:365.
    [10] Jiang ZF, Hu XC, Wang YS, et al. Current New Concept and Clinical Strategy of Whole Management of Breast Cancer[M]. Shanghai: Shanghai scientific and technical publishers, 2013: 365.
    [11] 周际昌.实用肿瘤内科治疗学[M].北京:北京科学技术出版社,2012:32.
    [12] Zhou JC. Practical Medical Treatment of Cancer[M]. Beijing: Beijing science and technology press, 2012: 32.
    [13] 邵超,张晶晶,凌飞海,等.三阴性乳腺癌中核因子κB的表达与临床病理及预后[J].中华普通外科学,2015,9(1):29-33.
    [14] Shao C,Zhang JJ, Lin FH, et al. Clinical pathology, prognosis and the expression of nuclear factor κB of triple negative breast cancer[J]. Chin Gen Surg, 2015, 9(1): 29-33.
    [15] 张彦,李曼,赵璐,等.乳腺癌不同剂量表柔比星联合辅助化疗的疗效分析[J].中华肿瘤防治杂志,2014, 21(15):1168-1173.
    [16] Zhang Y, Li M, Zhao L, et al. Effect analysis of different doses of pharmorubicin combining adjuvant chemotherapy on breast cancer[J]. Chin J Cancer Prevent Treat, 2014, 21(15): 1168-1173.
    [17] 马文玥.卡铂联合紫杉醇治疗局部晚期三阴性乳腺癌的Ⅱ期临床研究[D].北京:北京协和医学院,2011.
    [18] Ma WY. Phase Ⅱ Study of Neoadjuvant Carboplatin Plus Paclitaxel for Locally Advanced Triple-negative Breast Cancer[D]. Beijing: Peking Union Medical College, 2011.
    [19] Liu Q. Triptolide and its expanding multiple pharmacological functions[J]. Int Immunopharmacol, 2011, 11(3): 377-383.
    [20] 张建国,苏永华.华蟾酥毒基药理作用及剂型研究进展[J].浙江中医药大学学报,2009, 33(4):608-610.
    [21] Zhang JG, Su YH. Research development of dosage form and pharmacological action of cinobufagin[J]. J Zhejiang Coll Tradit Chin Med, 2009, 33(4): 608-610.
    [22] Wu MB, Wu YL, Zhou J, et al. Structural characteristation of a water-soluble polysaccharide with high branches from the leaves of Taxus chinensis var mairei[J]. Food Chem,2009,113:1020-1024.
    [23] 刘敏,章永红,颜晓静,等.杉蟾藤成分复方诱导ER(+)人乳腺癌MCF-7细胞凋亡的实验研究[J].南京中医药大学学报,2014, 30(3):267-271.
    [24] Liu M, Zhang YH, Yan XJ, et al. Experimental research on apoptosis mechanism of ER(+) human breast cancer MCF-7 cells induced by the compound components of Shanchanteng[J]. J Nanjing Univ Tradit Chin Med, 2014, 30(3): 267-271.
  • 加载中
计量
  • 文章访问数:  721
  • HTML全文浏览量:  4
  • PDF下载量:  711
  • 被引次数: 0
出版历程
  • 收稿日期:  2015-11-14
  • 修回日期:  2016-01-11
  • 刊出日期:  2016-03-10

目录

    /

    返回文章
    返回